Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

  • J. Aristegui
  • E. Bernaola
  • I. Pocheville
  • C. García
  • L. Arranz
  • G. Durán
  • L. Pérez
  • M. Bastida
  • C. Canduela
  • M. Herranz Aguirre
  • E. Garrote
  • M. A. Fletcher
  • C. Pérez


This study evaluated the incidence of invasive pneumococcal disease, identified the causal serotypes, and tracked the evolution of the antibiotic susceptibility of Streptococcus pneumoniae isolates in the regions of the Basque Country and Navarre, Spain, before and after the introduction of the heptavalent pneumococcal conjugate vaccine. The study included all children aged between birth and 5 years diagnosed with bacteremia, meningitis, or bacteremic pneumonia caused by pneumococci. By the second year after introduction of the heptavalent pneumococcal conjugate vaccine, compared with the period 1998–2001, the incidence of invasive disease decreased by 64.3% in children less than 12 months of age, by 39.7% in children less than 24 months of age, and by 37.5% in children less than 60 months of age. The prevalence of clinical isolates of S. pneumoniae that lacked susceptibility to penicillin decreased by 58.2% among children less than 60 months of age. With an estimated coverage by four-dose heptavalent pneumococcal conjugate vaccine of 28–45% in 2003, the number of invasive pneumococcal infections in the Basque Country and in Navarre fell significantly after just 2 years of immunization, underscoring the importance of improving vaccination coverage under a universal childhood immunization program.



This study was conducted with assistance in sample collection from the microbiological departments of Basurto Hospital, Virgen del Camino Hospital, Cruces Hospital, Complejo Hospitalario Donostia, Zumárraga Hospital, García Orcoyen Hospital, Txgorritxu Hospital, Santiago Apostol Hospital, and Alto Deba Hospital. We thank Cristina Fernández for technical support.

This study was funded in part by an unrestricted educational grant from Wyeth Lederle Vaccines.


  1. 1.
    Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin, L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187–195PubMedCrossRefGoogle Scholar
  2. 2.
    Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason EO Jr (2003) Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine. Pediatrics 111(4 Pt 1):896–899PubMedCrossRefGoogle Scholar
  3. 3.
    Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B (2004) Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23:485–489PubMedCrossRefGoogle Scholar
  4. 4.
    Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR (2004) Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 39:641–648PubMedCrossRefGoogle Scholar
  5. 5.
    Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Yogev R, Barson WJ (2004) Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113(3 Pt 1):443–449PubMedCrossRefGoogle Scholar
  6. 6.
    Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, and the Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746PubMedCrossRefGoogle Scholar
  7. 7.
    Pérez Mendez C, Solís Sanchez G, Miguel Martínez D, La Iglesia Martínez P, Viejo de la Guerra G, Martín Mardomingo MA (2002) Factores predictivos de enfermedad neumocócica invasora: estudio de casos y controles. An Esp Pediatr 57:310–316PubMedGoogle Scholar
  8. 8.
    Arístegui J, Bernaola Iturbe E, Pocheville Gurutzeta I, Perez-Yarza E, Arranz I, Durán G (2002) Incidence of invasive pneumococcal disease (IPD) in children from 0 to 23 months old in the Basque Country and Navarre (Spain). 20th Annual Meeting of the European Society for Paedriatic Infectious Diseases, Vilnius, LithuaniaGoogle Scholar
  9. 9.
    Casado Flores J, Fenoll A, Arístegui Fernandez J, Rodrigo De Liria C, Martinon Sanchez JM, Berron S, Fernandez Perez C, and the Grupo para el Estudio de la Meningitis Neumococica (2002) Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico. An Esp Pediatr 57:295–300PubMedGoogle Scholar
  10. 10.
    Casado-Flores J, Arístegui J, Rodrigo de Liria C, Martinon J, Fernández C (2002) Prevalencia de meningitis neumocócica en niños españoles. An Esp Pediatr 56:5–9PubMedGoogle Scholar
  11. 11.
    Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J, and the Massachusetts Department of Public Health Epidemiologists (2005) Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 24:17–23PubMedCrossRefGoogle Scholar
  12. 12.
    Eskola J, Takala AK, Kela E, Pekkanen E, Kalliokoski R, Leinonen M (1992) Epidemiology of invasive pneumococcal infections in children in Finland. JAMA 268:3323–3327PubMedCrossRefGoogle Scholar
  13. 13.
    Bjornson G, Scheifele D, Binder F, Talling D (2000) Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994–1998. Can Commun Dis Rep 26:149–151PubMedGoogle Scholar
  14. 14.
    Anonymous (1997) Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 46(RR-8):1–24Google Scholar
  15. 15.
    Blanco Quiros A, Gimenez Sanchez F, Asensi Botet F, Bernaola Iturbe E, Martin Fde J, Garcia Perez J, Garces Sanchez M, Gomez Campdera JA, Picazo JJ, Pineda Solas V, and the Comite Asesor de Vacunas de la Asociacion Espanola de Pediatria (2002) Incidencia de la infeccion neumococica invasora en ninos menores de dos anos. Vacuna neumococica conjugada heptavalente. Situacion en Espana. An Esp Pediatr 57:287–289PubMedGoogle Scholar
  16. 16.
    Bernaola Iturbe E, de Aristegui Fernandez J, Herranz Aguirre M, Garcia Calvo C, Fernandez Perez C, and the Grupo de Estudio de Enfermedad Invasora Neumococica en el Pais, Vasco-Navarra (2002) Estudio de la incidencia de enfermedad neumocócica invasora entre 0–5 años en el País Vasco y Navarra. An Esp Pediatr 57:301–309PubMedGoogle Scholar
  17. 17.
    National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. Approved standard M7-A5. NCCLS, Wayne, PAGoogle Scholar
  18. 18.
    Casal J (1982) Antimicrobial susceptibility of Streptococcus pneumoniae: serotype distribution of penicillin-resistant strains in Spain. Antimicrob Agents Chemother 22:222–225PubMedGoogle Scholar
  19. 19.
    Fenoll A, Casal J (2000) Estudio de los serotipos de Streptococcus pneumoniae en España. In: Campins Martí M, Moraga Llop F (eds) Vacunas 2000. Prous Science, Barcelona, pp 55–67Google Scholar
  20. 20.
    Thornsberry C, Ogilvie P, Kahn J, Mauriz Y (1997) Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 29:249–257PubMedCrossRefGoogle Scholar
  21. 21.
    Tomasz A (1997) Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 24(Suppl 1):S85–S88PubMedGoogle Scholar
  22. 22.
    Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J, and the Spanish members of the European Antimicrobial Resistance Surveillance System (2004) Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish Hospitals (2001 to 2003): decreasing penicillin resistance in children’s isolates. J Clin Microbiol 42:5571–5577PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • J. Aristegui
    • 1
  • E. Bernaola
    • 2
  • I. Pocheville
    • 3
  • C. García
    • 4
  • L. Arranz
    • 5
  • G. Durán
    • 6
  • L. Pérez
    • 7
  • M. Bastida
    • 8
  • C. Canduela
    • 9
  • M. Herranz Aguirre
    • 2
  • E. Garrote
    • 1
  • M. A. Fletcher
    • 10
  • C. Pérez
    • 11
  1. 1.Pediatric DepartmentBasurto HospitalBilbaoSpain
  2. 2.Pediatric DepartmentVirgen del Camino HospitalPamplonaSpain
  3. 3.Pediatric DepartmentCruces HospitalBarakalodoSpain
  4. 4.Pediatric DepartmentComplejo Hospitalario DonostiaSan SebastianSpain
  5. 5.Pediatric DepartmentZumárraga HospitalZumárragaSpain
  6. 6.Pediatric DepartmentGarcía Orcoyen HospitalEstella NavarraSpain
  7. 7.Pediatric DepartmentTxagorritxu HospitalVitoriaSpain
  8. 8.Pediatric DepartmentSantiago Apostol HospitalVitoriaSpain
  9. 9.Pediatric DepartmentAlto Deba HospitalMondragónSpain
  10. 10.Wyeth Vaccines ResearchParisFrance
  11. 11.Wyeth FarmaSan Sebastián de los ReyesSpain

Personalised recommendations